8-K filed January 30, 2024, 6:59 PM ET ticker HCA CIK 0000860730

earnings confidence high sentiment positive materiality 0.85

HCA Healthcare Q4 revenue up 11.6% to $17.3B; FY2024 EPS guidance $19.70-$21.20; CFO succession announced

HCA Healthcare, Inc.

2023-FY EPS reported $18.97 revenue$64,968,000,000

Q4 2023 revenue $17.303B (+11.6% YoY); net income $1.607B ($5.93 diluted EPS) vs $2.081B ($7.28) in Q4 2022, which included $1.326B gain.
Adjusted EBITDA $3.618B (up from $3.179B); same facility admissions +3.1%, equivalent admissions +3.9%.
FY2024 guidance: revenue $67.75-$70.25B, Adjusted EBITDA $12.85-$13.55B, diluted EPS $19.70-$21.20; capex $5.1-$5.3B.
Board authorized additional $6B share repurchase program; quarterly dividend declared at $0.66 per share (unchanged).
CFO Bill Rutherford retiring May 1, 2024; succeeded by Mike Marks, current SVP Finance.

item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael A. Marks

Executive Vice President and Chief Financial Officer

HCA · HCA Healthcare, Inc.

Effective: 2024-05-01
Filed: January 30, 2024, 6:59 PM ET

On January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024.

Departed

William B. Rutherford

Executive Vice President and Chief Financial Officer

HCA · HCA Healthcare, Inc.

Effective: 2024-05-01
Successor: Michael A. Marks
Filed: January 30, 2024, 6:59 PM ET

On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HCA Healthcare, Inc. reported 2024 results: revenue $67.75 to $70.25 billion, net income $5.20 to $5.60 billion, EPS $19.70 to $21.20 per diluted share. Guidance initiated.

Period: 2024
Revenue: $67.75 to $70.25 billion
Net income: $5.20 to $5.60 billion
EPS: $19.70 to $21.20 per diluted share
Guidance: initiated
Result: guidance update

Exact text from the filing

Today, the Company issued the following estimated guidance for 2024: 2024 Guidance Range Revenues $67.75 to $70.25 billion Net Income Attributable to HCA Healthcare, Inc. $5.20 to $5.60 billion Adjusted EBITDA $12.85 to $13.55 billion EPS (diluted) $19.70 to $21.20 per diluted share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HCA Healthcare, Inc. reported the year ended December 31, 2023 results: revenue $64.968 billion, net income $5.242 billion, EPS $18.97 per diluted share. Guidance initiated.

Period: the year ended December 31, 2023
Revenue: $64.968 billion
Net income: $5.242 billion
EPS: $18.97 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

Revenues for the year ended December 31, 2023 totaled $64.968 billion, compared to $60.233 billion for the year ended December 31, 2022. Net income attributable to HCA Healthcare, Inc. was $5.242 billion, or $18.97 per diluted share, for the year ended December 31, 2023 compared to $5.643 billion, or $19.15 per diluted share, for the year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HCA Healthcare, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $17.303 billion, net income $1.607 billion, EPS $5.93 per diluted share. Guidance initiated.

Period: the fourth quarter ended December 31, 2023
Revenue: $17.303 billion
Net income: $1.607 billion
EPS: $5.93 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

Revenues in the fourth quarter of 2023 totaled $17.303 billion, compared to $15.497 billion in the fourth quarter of 2022. Net income attributable to HCA Healthcare, Inc. totaled $1.607 billion, or $5.93 per diluted share, compared to $2.081 billion, or $7.28 per diluted share, in the fourth quarter of 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael A. Marks was appointed as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

William B. Rutherford retired as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..

Action: retired
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

HCA Healthcare, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-018748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.